CARsgen Therapeutics Holdings 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zonghai Li

최고 경영자

CN¥2.1m

총 보상

CEO 급여 비율	50.2%
CEO 임기	3.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?

Aug 31

CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Jan 23

Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

Sep 05

CEO 보상 분석

Zonghai Li 의 보수는 CARsgen Therapeutics Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥695m
Mar 31 2024	n/a	n/a	-CN¥721m
Dec 31 2023	CN¥2m	CN¥1m	-CN¥748m
Sep 30 2023	n/a	n/a	-CN¥834m
Jun 30 2023	n/a	n/a	-CN¥920m
Mar 31 2023	n/a	n/a	-CN¥906m
Dec 31 2022	CN¥2m	CN¥1m	-CN¥892m

보상 대 시장: Zonghai 의 총 보상 ($USD 288.21K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 396.35K ).

보상과 수익: 회사가 수익성이 없는 동안 Zonghai 의 보상이 증가했습니다.

CEO

Zonghai Li (50 yo)

3.8yrs

테뉴어

CN¥2,084,000

보상

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zonghai Li	Co-Founder	3.8yrs	CN¥2.08m	데이터 없음
Huamao Wang	Co-Founder	3.8yrs	CN¥2.11m	데이터 없음
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	데이터 없음
Hong Ma	Senior Vice President of Clinical Development	no data	데이터 없음	데이터 없음
Leigh Hsu	Senior Vice President of Business Development	no data	데이터 없음	데이터 없음
Raffaele Baffa	Chief Medical Officer	2.6yrs	데이터 없음	데이터 없음
Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	2.1yrs	데이터 없음	데이터 없음
Wing Yat Lui	Company Secretary	3.8yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 2171 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zonghai Li	Co-Founder	6.8yrs	CN¥2.08m	데이터 없음
Huamao Wang	Co-Founder	6.2yrs	CN¥2.11m	데이터 없음
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	데이터 없음
Ronggang Xie	Non-Executive Director	4.2yrs	데이터 없음	데이터 없음
Xiangke Zhao	Independent Non-Executive Director	1.3yrs	CN¥80.00k	데이터 없음
Bingsen Guo	Non-Executive Director	6.2yrs	데이터 없음	1.62% HK$ 54.2m
Guangmei Yan	Independent Non-Executive Director	3.4yrs	CN¥222.00k	데이터 없음
Huaqing Guo	Non-Executive Director	4.2yrs	데이터 없음	0.38% HK$ 12.7m
Wen Zhou	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 이사회: 2171 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.

CARsgen Therapeutics Holdings 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Non-Executive Director recently bought HK$903k worth of stock

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Recent updates

New major risk - Share price stability

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

CARsgen Therapeutics Holdings Limited has completed an IPO in the amount of HKD 3.107702 billion.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령